2023-06-02T04:51:08
UNDERTAKING BY THE INVESTIGATOR
1. Full name, address and title of the Principal Investigator (or Investigator(s)
when there is no Principal Investigator).
2. Name and address of the medical college, hospital or other facility where
the Clinical Investigation will be conducted: Education, training
& experience that qualify the Investigator for the clinical investigation
Central Drugs Standard Control Organization, Ministry of Health and Family Welfare, Govt. of India Page 195 of 248
(Attach details including medical council registration number, or any other
statement(s) of qualification(s)).
3. Name and address of all clinical facilities to be used in the clinical
investigation.
4. Name and address of the Ethics Committee that is responsible for approval
and continuing review of the clinical investigation.
5. Names of the other members of the research team (Co-Investigators or
sub-investigators) who will be assisting the Investigator in the conduct of
the investigation(s).
6. Clinical Investigation Plan, Title and Clinical investigation number (if
any) of the clinical investigation to be conducted by the Investigator.
7. Commitments:
(i) I have reviewed the clinical investigation plan and agree that it
contains all the necessary information to conduct the investigation. I
will not begin the clinical investigation until all necessary Ethics
Committee and regulatory approvals have been obtained.
(ii) I agree to conduct the investigation in accordance with the current
Clinical investigation plan. I will not implement any deviation from or
changes of the Clinical investigation plan without agreement by the
Sponsor and prior review and documented approval/favorable opinion
from the Ethics Committee of the amendment, except where necessary
to eliminate an immediate hazard(s) to the clinical investigation
participant or when the change(s) involved are only logistical or
administrative in nature.
(iii) I agree to personally conduct and/or supervise the clinical
investigation at my site.
(iv) I agree to inform all Subjects that the medical devices are being
used for investigational purposes and I will ensure that the
requirements relating to obtaining informed consent and Ethics
Committee review and approval specified in this Schedule are met.
(v) I agree to report to the Sponsor all adverse experiences that occur
in the course of the investigation(s) in accordance with the regulatory
and Good Clinical practice guidelines.
Central Drugs Standard Control Organization, Ministry of Health and Family Welfare, Govt. of India Page 196 of 248
(vi) I have read and understood the information in the Investigator's
brochure, including the potential risks and side effects of the medical
device.
(vii) I agree to ensure that all associates, colleagues and employees
assisting in the conduct of the clinical investigation are suitably
qualified and experienced and they have been informed about their
obligations in meeting their commitments in the clinical investigation.
(viii) I agree to maintain adequate and accurate records and to make
those records available for audit/inspection by the Sponsor, Ethics
Committee, Licensing Authority or their authorized representatives, in
accordance with regulatory and provisions of these rules. I will fully
cooperate with any clinical investigation related audit conducted by
regulatory officials or authorized representatives of the Sponsor.
(ix) I agree to promptly report to the Ethics Committee all changes in
the CIP activities and all unanticipated problems involving risks to
human Subjects or others.
(x) I agree to inform all serious adverse events to the Sponsor,
Central Licensing Authority as well as the Ethics Committee within
forty-eight hours of their occurrence. In case of failure, I will submit
the justification to the satisfaction of the Central Licensing Authority. I
also agree to report the serious adverse events, after due analysis, to the
Central Licensing Authority, Chairman of the Ethics Committee and
head of the institution where the investigation has been conducted
within fourteen days of the occurrence of serious adverse events.
(xi) I will maintain confidentiality of the identification of all
participating clinical investigation patients and assure security and
confidentiality of clinical investigation data.
(xii) I agree to comply with all other requirements, guidelines and
statutory obligations as applicable to clinical Investigators participating
in clinical Investigations.
Date: Signature of Investigator
Have a question? Ask here!
Required fields are marked *